22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purinergic signalling appears to play important roles in neurodegeneration, neuroprotection and neuroregeneration. Initially there is a brief summary of the background of purinergic signalling, including release of purines and pyrimidines from neural and non-neural cells and their ectoenzymatic degradation, and the current characterisation of P1 (adenosine), and P2X (ion channel) and P2Y (G protein-coupled) nucleotide receptor subtypes. There is also coverage of the localization and roles of purinoceptors in the healthy central nervous system. The focus is then on the roles of purinergic signalling in trauma, ischaemia, stroke and in neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, as well as multiple sclerosis and amyotrophic lateral sclerosis. Neuroprotective mechanisms involving purinergic signalling are considered and its involvement in neuroregeneration, including the role of adult neural stem/progenitor cells. This article is part of the Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'.

          Related collections

          Author and article information

          Journal
          Neuropharmacology
          Neuropharmacology
          Elsevier BV
          1873-7064
          0028-3908
          May 2016
          : 104
          Affiliations
          [1 ] Autonomic Neuroscience Centre, University College Medical School, Rowland Hill Street, London NW3 2PF, UK; Department of Pharmacology and Therapeutics, The University of Melbourne, Australia. Electronic address: g.burnstock@ucl.ac.uk.
          Article
          S0028-3908(15)00212-9
          10.1016/j.neuropharm.2015.05.031
          26056033
          56eafb6b-32b3-4295-a076-2bdecf70a9af
          History

          γ-Amino butyric acid (GABA) (PubChem CID: 119),β-Amyloid(1–42) (PubChem CID: 57339251),Stem cells,Pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS) (PubChem CID: 6093163),Parkinson's,N-methyl-D-aspartate (NMDA) (PubChem CID: 22880),MS,Interleukin 1β (PubChem CID: 123872),Diadenosine tetraphosphate (AP(4)A) (PubChem CID: 21706),Brilliant Blue G (BBG) (PubChem CID: 6328534),Alzheimer's,Adenosine (PubChem CID: 60961),ATP (PubChem CID: 5957),ATP,ALS,2′- and 3′-O-(4-benzoylbenzoyl)-ATP (BzATP) (PubChem CID: 115205)

          Comments

          Comment on this article